July - September 2017, Volume 13, Issue 3

Bonakdaran S, Khorasani ZM, Jafarzadeh F

Increased Serum Level of FGF21 in Gestational Diabetes Mellitus

Acta Endo (Buc) 2017, 13 (3): 278-281
doi: 10.4183/aeb.2017.278

Objective. Gestational diabetes mellitus (GDM) is a common endocrine complication in pregnancy. There are few risk factors that clearly correlate with GDM. Fibroblast growth factor 21 (FGF21) is a metabolic hormone that can regulate glucose metabolism. It has been recognized that serum levels of FGF21 are significantly increased in diabetes and insulin resistance states. The objective of this study was to determine the serum FGF21 levels in women with GDM compared with non-GDM women and its correlation with insulin resistance. Methods. Thirty GDM patients and 60 healthy pregnant controls that matched for maternal and gestational age were selected. Women with previous history of GDM, hypertension, polycystic ovary syndrome, renal or liver failure and drug consumption with effects on glucose or insulin levels were excluded. FGF21 was determined and correlated with biochemical parameters of glucose metabolism and insulin resistance. Results. FGF21 concentration was significantly higher in GDM (264.5±196.2 ng/L) as compared with control groups (59.1±36.5ng/L). Correlation of FGF21 with insulin resistance was not significant. A cut-off 82.07 ng/L of FGF21 had sensitivity of 100% and specificity of 85% for prediction of GDM. Conclusion. FGF21 is increased in GDM and it is independent of insulin resistance. We suggest that FGF21 resistance could be directly involved in pathophysiology of GDM.

Keywords: GDM, FGF21, pregnancy, insulin resistance

Correspondence: Shokoufeh Bonakdaran, Associate Professor of Endocrinology, Mashhad University of Medical Sciences, Faculty of Medicine, Ghaem Hospital, Endocrine Research Center, 91766, Mashhad, Iran, E-mail: bonakdaransh@mums.ac.ir